Denali, Takeda end work on Phase I Alzheimer’s drug with ‘narrow therapeutic window’

As Biogen takes a preclinical Denali compound targeting amyloid beta forward in Alzheimer’s, Denali is shelving another Alzheimer’s candidate that is partnered with Takeda and hits a different target.

Phase I data suggest that the drug, known as TAK-920 or DNL919, has a “narrow therapeutic window” given safety signals, Denali…
Click here to view original post